Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug source : Www.globenewswire.com save search
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
LSTA | $2.78 -5.82% 1.1K
|
Manufacturing
|
| O: 0.34%
H: 9.62%
C: 3.78%
fda drug granted treatment designation for therapeutics
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
NXTC | $1.57 3.97% 3.82% 39K
|
Health Technology
|
| O: 0.93%
H: 1.38%
C: -5.53%
drug antibody preclinical
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
BETR | $0.45 -0.51% -0.51% 520K
|
n/a
|
| O: -0.96%
H: 0.97%
C: -0.95%
BETRF | $0.077 -3.71% 34K
|
Health Technology
|
| O: -7.53%
H: 7.0%
C: 7.0%
betr-001 drug candidate million
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0672 178.69% 100
|
Health Technology
|
| O: 0.37%
H: 4.5%
C: -11.69%
drug stroke pharmaceuticals research program
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
SLGL | $0.9001 5.04% 4.8% 3.5K
|
Health Technology
|
| O: 2.03%
H: 4.0%
C: -0.49%
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: -2.81%
zoryve drug collaboration
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
| Email alert
Add to watchlist
can-3110 drug presentation update trial therapeutics glioblastoma
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
PPBT | $0.4701 8.24% 7.62% 170K
|
Manufacturing
|
| O: 0.0%
H: 8.06%
C: 8.06%
nt219 drug biotech purple
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
MIST | $1.57 -10.29% -11.46% 210K
|
Health Technology
|
| O: 4.44%
H: 0.0%
C: 0.0%
etripamil drug tachycardia resubmission treatment pharmaceuticals application milestone
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
IBIO | $1.77 -6.35% -0.57% 180K
|
Health Technology
|
| O: 133.04%
H: 0.0%
C: 0.0%
obesity drug collaboration
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Published: 2024-03-26 (Crawled : 03:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Published: 2024-03-20 (Crawled : 13:00) - globenewswire.com
CELU | News F | $3.17 -4.23% -4.42% 42K
|
|
| O: 4.02%
H: 0.74%
C: 0.74%
pda-002 fda drug designation
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
CABA | $13.96 -7.86% -8.52% 1.1M
|
Health Technology
|
| O: 0.0%
H: 1.44%
C: 0.67%
caba-201 fda drug granted sclerosis treatment designation
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
NVDA | News | $847.15 0.81% 0.83% 44M
|
Electronic Technology
|
| O: -1.98%
H: 4.43%
C: 3.11%
drug health nvidia
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.54 -8.29% -9.04% 190K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
Published: 2024-03-14 (Crawled : 13:00) - globenewswire.com
BGXX | $0.2299 5.46% 5.18% 420K
|
|
| O: 6.76%
H: 6.47%
C: -10.23%
drug continuation million solar expansion
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
PLUR | $5.02 -2.9% -2.99% 12K
|
Manufacturing
|
| O: 0.55%
H: 0.95%
C: -3.09%
drug cell
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PEPG | $11.9 3.48% 3.36% 47K
|
|
| O: 1.94%
H: 4.94%
C: -2.9%
edo51 fda rare drug disease treatment duchenne
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Published: 2024-03-12 (Crawled : 15:00) - globenewswire.com
BGXX | $0.2299 5.46% 5.18% 420K
|
|
| O: -0.14%
H: 158.62%
C: 45.93%
drug million expansion
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.